<< Exhibitor
<< Press release
The 23rd China International In Vitro Diagnostic Expo by CACLP and its concurrent activities will return from 21–23 March 2026, at the Xiamen International Expo Center in Fujian Province, China.
On June 4 2025, Elsevier officially released the 2024 CiteScore, a key metric used to assess the impact of academic journals. VIEW, jointly sponsored by China Professional Community of Experimental Medicine (CPCEM) and published by John Wiley & Sons, achieved a CiteScore of 14.5 for 2024.
From 18-22 May 2025, Brussels, Belgium, hosted the 26th IFCC-EFLM EUROMEDLAB Congress of Clinical Chemistry and Laboratory Medicine and the 49th Annual Meeting of the Royal Belgian Society of Laboratory Medicine.
The 22nd China International In Vitro Diagnostics Expo by CACLP and the 5th China IVD Supply Chain Expo (CISCE) took place from 22–24 March 2025 in Hangzhou, achieving unprecedented scale and impact.
With just two weeks to go, anticipation is building for the 22nd China International In Vitro Diagnostic Expo by CACLP, the largest and most influential gathering of the IVD industry in China! Taking place 22-24 March 2025, at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025 promises to be a world-class showcase of the latest innovations, professional networking and business opportunities.
The 7th China IVD Distribution Enterprise Forum is set to take place on 23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.
Welcome to the 22nd China International In Vitro Diagnostic Expo by CACLP & 5th China IVD Supply Chain Expo!
The 1st National Primary Healthcare Laboratory Forum is a key event focused on strengthening primary healthcare laboratory testing, which plays a vital role in early disease diagnosis and treatment outcomes.
As China’s pet market continues to flourish, with rising pet ownership and increasing per capita spending, the demand for quality veterinary care is rapidly growing.
<< Industry news
The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of the industry's first liquid qPCR master mixes proven stable for over 12 months at ambient temperatures and shippable with oligos without compromising performance. This breakthrough eliminates the need for refrigeration, freezing, or costly lyophilization (freeze-drying), offering a level of flexibility and convenience not previously available in liquid formats. With superior performance, these new mixes expand Meridian's portfolio of ambient-stable molecular reagents while simplifying logistics, reducing costs, and delivering sustainable solutions for assay developers and high-throughput automation users across all settings — from point-of-care (POC) to centralized labs.
Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the first-ever Premarket Approval (PMA) from the FDA for a cartridge-based, fully automated, “sample-to-result” companion diagnostic test.
Roche (SIX: RO, ROG; OTCQX: RHHBY) shared real-world evidence from the rollout of Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution at the European Association for the Study of Diabetes (EASD) annual meeting today, and announced its integration with the mySugr diabetes management app, providing many more people with diabetes access to an AI-enabled predictive solution for the first time.
Digital pathology firm Proscia announced on Tuesday that it has expanded its collaboration with Amazon Web Services by integrating Proscia's Concentriq pathology platform with AWS HealthImaging, a service for storing and sharing whole-slide images in the cloud.
China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.
Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children’s Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers present in urine, funded in part by the National Institutes of Health. This approach could significantly reduce the need for invasive, often painful biopsies, they say.
<< Video showcase
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
<< Download centre
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
CACLP & CISCE 2024 - Floor Plan
CACLP & CISCE 2024 - Exhibitor Manual
1200+ Global Exhibitors Confirmed Their Participation on the 21st CACLP and 4th CISCE in Chongqing, March 2024
CACLP & CISCE 2023 Post-show Report
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
